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Real-Time PCR in the early detection of invasive fungal infection in 
immunodeficient infants and children  
 
INTRODUCTION 
Invasive fungal infections (IFI) in children appear 
to have increased over the past two decades. 
Among immunocompromised children, the impact 
of IFI can be devastating, with a high rate of 
mortality and morbidity. Timely diagnosis and 
initiation of appropriate antifungal therapy is 
imperative for improving outcomes.1  
Although conventional diagnostic tests such as 
histology, microscopy, and culture remain the 
cornerstone of proving fungal disease, their yield is 
low and, therefore, their impact on clinical 
decisions to treat patients is limited. Invasive 
procedures such as biopsy of the infected site may 
be precluded due to the presence of severe 
thrombocytopenia. Furthermore, cultures become 
positive at a late stage of infection and delayed 
therapy is associated with a poor outcome.2,3  
Candida and Aspergillus species are the most 
commonly isolated organisms.1  Since non-albicans 
Candida species and non-fumigatus Aspergillus 
species are increasing in importance, new 
diagnostic approaches covering a large number of 
fungal species are required.3,4   Several studies have 
demonstrated the principle feasibility of detecting 
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molds and yeast DNA in a single reaction using the 
universal fungal primer.5,6 The introduction of real-
time PCR technology in the detection of fungal 
infections has increased the realibilty of PCR 
results compared to results obtained by 
conventional PCR. The absence of post-PCR 
processing after amplification has sharply decreased 
the risk of false positive reactions which might 
occur during the use of acrylamid or agarose gel 
electrophoresis. Moreover, real-time PCR can give 
the results in less than 2 hours, a requirement for 
clinical decision making.7   
This study aimed to evaluate the role of real-
time PCR in the early diagnosis of IFI in 
immunocompromised patients who lack clinical 




This study included 30 patients with 
immunodeficiency (9 with primary and 21 with 
secondary immunodeficiency) suspected to have 
IFI. They were consecutively enrolled from the 
Pediatric Allergy and Immunology, Hematology 
and Oncology, and Intensive Care units of Ain 
Shams University, Children′s Hospital during the 
period from June 2009 to August 2010. They were 
9 females and 21 males with ages ranging from 3 
months to 14 years. An informed consent was 
obtained from the patients' parents or care-givers 
before enrollment. The study gained the approval of 
the Ethicas′ Committee of the Department 
Pediatrics, Ain Shams University. 
Twenty seven patients had fever and three had 
bronchopneumonia, both not responding to broad 
spectrum antibiotics for a minimum of 96 hours. As 
per the European Organization for Research and 
Treatment of Cancer/Invasive Fungal Infections 
Cooperative Group and the National Institute of 
Allergy and Infectious Diseases Mycoses Study 
Group (EORTC/MSG) criteria for IFI, all patients 
had at least one host factor but lacked the 
characteristic clinical and imaging signs of proven 
or probable IFI.8   
A three-page sheet was constructed to collect 
necessary data through:  
Clinical history taking: with special emphasis on 
details of the original immunodeficiency disease, 
symptoms suggestive of local and/or systemic 
infection, type, dose and duration of 
immunosuppressive therapy including 
corticosteroids and the antibiotics and/or 
antifungals received.  
Physical examination: including body temperature 
recording, examination of the oral cavity for ulcers 
or thrush, looking for nasal ulcers or sinusitis, chest, 
abdominal and CNS examination, as well as 
looking for perineal rash. 
Imaging studies: including plain radiographs, 
computed tomography scans, and MRI of suspected 
sites; done as needed. 
Urine analysis and serum biochemical 
evaluation of liver and kidney functions were done 
for all patients in addition to Complete Blood 
Count, CRP titre and Erythrocyte Sedimentation 
Rate. 
Microbiologic assessment: 
1-Blood sampling  
Five milliliters of venous blood were withdrawn 
from each patient under complete aseptic condition: 
0.5-1.5ml were added to the blood culture bottle for 
fungal culture and 3 ml were mixed with EDTA in 
a tube and stored at -20°C until performance of 
PCR.  
2-Blood culture 
The blood culture bottles were incubated 
aerobically at 35°C and were subcultured every 48 
hours onto two Sabaroud’s dextrose agar and one 
blood agar (Oxoid, England) plates until growth 
was detected or the bottle was discarded after two 
weeks. One Sabaroud’s dextrose agar and the blood 
agar plates were incubated at 35°C for detection of 
Candida and bacterial isolates. The other 
Sabaroud’s dextrose agar plate was left at room 
temperature for upto 2 weeks for detection of 
filamentous fungal growth. All isolates were 
identified according to Collee et al.9 and Milne et 
al.10 based on colony morphology, microscopic 
examination of Gram-stained film and their 
biological activity. 
3-Real-time PCR for detection of fungal infection 
Total DNA was extracted using MagNA pure 
compact nucleic acid isolation kit I 
(Cat.No.03730964001, Roche, Germany) according 
to manufacturer’s protocol. Universal fungal 
primers as described by White et al. (11) were used 
for amplification. The sequence of primers is ITS1: 
5'-TCCGTAGGTGAACCTGCGG-3' and ITS 4: 5'-
TCCTCCGCTTATTGATATG-3'. The ITS region 
primers make use of conserved regions of the 18S 
(ITS 1) and the 28S (ITS 4) rRNA genes to amplify 
the intervening 5.8S gene and the ITS 1 and ITS 2 
noncoding regions. For detection of aspergillus in 
positive samples for fungal infection, the sequence 
of the primers used were 5’-TTG GTG GAG TGA 
TTT GTC TGC T-3’ and 5’-CTA AGG GCA TCA 
CAG ACC TG 3’, which target Aspergillus-specific 
sequences of the fungal 18S rRNA gene.12 
Amplification was carried out in the LightCycler 
2.0 System (Roche, Germany) using LightCycler-
PCR in early detection of IFI in immunodeficiency 
  69
DNA master SYBR green amplification kit 
(Cat.No. 2015099, Roche, Germany).  
 
Statistical Methods: 
Statistical analysis was performed using the 
Statistical Package for the Social Sciences (SPSS, 
version15). Data were expressed as mean ±SD 
(range) or as number (%) of cases. Comparison of 
proportions and means between both groups was 
made by using the χ2 (Chi square test) and 
independent t-test, respectively. The Fisher’s exact 
test was used when applicable. Unpaired (student’) 
t test was used to test the difference between mean 
values of laboratory parameters, Non parametric 
data as platelets, age, and weight were presented as 
median and interquartile range (IQR) and were 
analyzed using Mann-Whitney test. The level 
P<0.05 was considered the cut-off value for 
significance. Kappa test was done to measure the 
agreement between two observers. 
 
RESULTS 
The demographic, clinical and some laboratory data 
of patients are presented in table (1). Of the studied 
children, 21 (70%) had secondary immune-
deficiency. The etiology of 2ry immunodeficiency 
was as follows: 8 had acute lymphoblastic 
leukemia; ALL (38.1%), four had acute 
myeloblastic leukemia; AML (19.04%), four had 
neuroblastoma (19.04%), four had lymphoma 
(19.04%) and one with Wilms tumor (4.7%). The 
remaining 9 children (30%) with primary 
immunodeficiency had their diagnoses as follows: 
three had congenital neutropenia, two had severe 
combined immunodeficiency (SCID), two with 
chronic granulomatous disease, one with Wiscott 
Aldrich syndrome and one with Omenn disease.  
The 9 patients with 1ry immunodeficiency had one 
host factor, while all patients with 2ry 
immunodeficiency had two or more host factors 
according to the EORTC MSG criteria.8 All patients 
with 2ry immunodeficiency were neutropenic and 
80.95% of them were treated with antifungal, while 
only 22.2% of 1ry immunodeficiency were 
neutopenic and 88.8% of them were treated with 
antifungal (Figure 1). 
Bacteremia was detected in 3 patients: one had 
Staphylococcus aureus, 1 had Acinetobacter 
baumannii and the third had Pseudomonas 
aeruginosa. These three patients had negative blood 
cultures for fungi, but by PCR, the first two were 
positive for Aspergillus and Candida, respectively. 
Blood culture detected 2 instances of fungal 
infection, namely Candida, while panfungal PCR 
detected 17 (57.7%) including those afore-
mentioned two instances of Candida. Hence 15 
patients (88% of the positive patients and 50% of 
all) were missed by blood culture. Statistically, 
there was no agreement between the results of 
blood culture and panfungal PCR k=0.10 P>0.05 as 
shown in table (2).  Blood culture had a sensitivity 
of 12% (2/17), specificity of 100% (13/13), PPV of 
100% and a NPV of 46% with diagnostic accuracy 
of 50%. 
Of the 17 positive cases by panfungal PCR, 6 
patients were positive for Aspergillus by the 
Aspergillus-specific PCR, hence, 11 patients were 
considered suffering of candidemia.  While 2 of 
these patients with candidemia were detected by 
blood culture, the other 9 patients were missed by 
blood culture. Furthermore, none of the 6 patients 
with positive PCR for Aspergillus was detected by 
blood culture.  
Of the 9 primary immunodeficiency children, 6 
(66.6%) had positive PCR results: 2 for Aspergillus 
and four were considered Candida. Concerning 
children with secondary immunodeficiency, 11/21, 
i.e. 52.3% had positive PCR results: four for 
Aspergillus and 7 considered were Candida. 
Therefore, nearly one third of the patients with 
PCR-proven fungal infection had invasive 
aspergillosis (IA). IA was seen in 2 SCID patients 
and 4 neutropenic cancer children while invasive 
candidosis (IC) was seen in a patient with Wiscott 
Aldrich, a patient with Omenn's disease, two with 
congenital neutropenia and 7 neutropenic cancer 
children. 
All the three patients with bronchopneumonia 
and half of those with fever not responding to 
antibiotics proved to have IFI. The results of PCR 
did not differ with age, gender type, degree of fever 
(< or >39oC), type of immunodeficiency (1ry or 2ry), 
clinical presentation, current intake of antifungal 
treatment, weight, duration of current illness, 
duration of antibiotics, and laboratory parameters. 
Patients with fungal infection, showed significantly 
increased CRP level when compared to those 
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Table 1. Demographic, clinical and laboratory data of patients. 
Variable Results 
Age(months) Median(IQR ):  48.00(78.5) 
Weight (Kg) Median(IQR ):   13.00(14) 
Weight Percentile (%) Median(IQR ):   5.00(7) 
Duration of current illness (days) Mean ±SD:  8.23±4.58 
Duration of antibiotic (days) Mean ±SD:  8.23±4.58 
Duration of antifungal (days) Mean ±SD:  3.43±3.73 
White blood cell (x103/mm3) Mean ±SD:  3.78±5.64 
Neutrophil % Mean ±SD:  33.37±19.63 
Absolute neutrophil count Mean ±SD:  1520±2640 
Lymphocytes% Mean ±SD 51.38±23.07 
Absolute lymphocytic count Mean ±SD:  1820±3250 
Hemoglobin (gm/dl) Mean ±SD:  9.01±2.22 
C reactive protein CRP Mean ±SD:  43.93±36.20 
Platelets (x103/mm3)* Median(IQR ): 112(265.75) 
Eryhrocyte sedimentation rate ESR Mean ±SD:  38.67±23.69 
IQR: interquartile range 
 
 
Table 2. Comparison between blood culture and panfungal PCR in detection of fungal infection. 
Variable 
Panfungal PCR results 
k P Sig.Negative(13) Positive (17)
N % N % 
Fungal blood culture results 
Negative (28) 13 43.3% 15 50.0% 
0.10 0.20 NS 
Positive (2) 0 0.0% 2 6.7% 




Figure 1. Neutropenic patients and patients on antifungal therapy among 
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P <0.05: significant 




The results of this study revealed that fungal 
infection was proved in 17/30 (56.7%) of the 
enrolled immunocompromised patients with 
suspected fungal infection by panfungal PCR; 
15/17 of these were missed by blood culture. 
Discrepancies in the results of culture and PCR are 
well known and have already been observed in 
previous studies.13 Detection of fungemia by means 
of fungal blood culture is notoriously difficult and 
IFIs are diagnosed better by molecular assay as 
naked DNA can be detected by PCR due to the 
presence of dead and degrading fungi within 
circulating phagocytes.14  
Badiee et al.15 studied the microbiologic data 
of 310 immunocompromised patients (recipients 
who underwent transplantation and leukemic 
patients with neutropenia on chemotherapy) and 
compared them with molecular methods. Results of 
their study revealed that 10.6% of patients had 
positive cultures for fungal infections whereas 
17.7% were positive for fungal infection by 
panfungal PCR. Another study compared results of 
culture, histology, galactomannan ELISA and real-
time PCR in tissues and blood samples, and stated 
that 20 samples (64.5%) were positive by both 
culture and real-time PCR, 6 samples (19.4%) 
showed no growth of fungi but were positive by 
real-time PCR and, the remaining samples (16.1%) 
were negative by both culture and PCR. Worth 
mentioning is that all of the tissue samples were 
positive by both PCR and histology.16  
According to the EORTC-MSG criteria, our 
patients at the outset of the study did not have 
possible (or proven) IFI. However, they were 
suspected of having fungal infection based on the 
existence of at least one host factor and the 
presence of fever or bronchopneumonia not 
responding to broad spectrum antibiotics. After 
performing mycological culture, 2 patients only 
turned out to have EORTC-MSG proven IFI when 
in fact another 15 did have PCR-proven IFI 
although they remained as not EORTC-MSG 
possible or probable, not to say proven IFI cases. 
This highlights the need for a more updated, patient 
and doctor-friendly criteria for diagnosis of IFI.   
Landinger et al,17 had focused on this 
correlation between PCR positive patients and the 
presence of proven, probable, and possible criteria 
of IFI according to the EORTC-MSG criteria; 150 
febrile neutropenic episodes in pediatric patients 
with high risk of IFI were investigated by panfungal 
PCR in his study, all proven, probable IFI, and all 
but one case with possible IFI were PCR positive. 
In 48 febrile episodes, patients received empirical 
antifungal on basis of clinical suspicion of IFI 
which did not meet any criteria of even possible 
fungal disease (EORTC IFI-ve). Twenty five of the 
episodes were positive by panfungal PCR; the 
sensitivity and NPV were in the range of 100%.  In 
another study taking 2 consecutive positive results 
as the diagnostic criterion for IA, the sensitivity, 
specificity, PPV, and NPV of PCR were 91.6%, 
94.4%, 73.3%, and 98.5%, respectively.18 Flourent 
et al.19 on the basis of the analysis of  serum 
samples from 51 patients with IA as defined by the 
EORTC-MSG (4 proven, 29 probable, 18 possible), 
results of PCR-ELISA for Aspergillus was assessed 
in comparison with the results of  high-resolution 
CT (HRCT), histological, and microbiological 
criteria as defined by the EORTC-MSG, and found 
that the sensitivity, specificity, PPV and NPV of 
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PCR-ELISA for proven and propable IFI were 
63.6%, 89.7%, 63.6%, 89.7% respectively, while 
the combination of PCR-ELISA and galactomannan 
(GM) assay raised the sensitivity to 83.3%, increase 
the NPV to 97.6%, and decrease the specificity to 
69.8%.  
In the present study, patients were in an early 
stage of IFI. Hence, the time factor could offer 
another explanation for the observed differences in 
the results of blood culture and PCR.  According to 
Estrella and coworkers 10 (18), fungal DNA was 
detected by PCR much earlier than GM in patients 
with aspergillosis and than HRCT detecting the 
lesions compatible with IFI. The mean time gain 
was 21 days compared with HRCT and 68 
compared with GM. 
The most common presentation in our PCR-
proven IFI immunodeficient patients was fever not 
responding to broad spectrum antibiotics (82.4%). 
In the study of Kobayashi et al,20 the most common 
infected region in 26 immunocompromised patients 
with IFI was the lung (54%), the liver (19%), while 
fungemia was present in 7.6%. Other researchers 
studied the most common presentation and found 
that in 44 patients with invasive candidiasis, 34 
patients presented with candidemia, whereas among 
10 patients with invasive aspergillosis, 8 patients 
presented with lung disease.21 
Invasive aspergillosis predominantly affects 
patients with compromised phagocytic immunity, 
such as neutropenic cancer patients.22 IA originating 
from colonized pneumatocele is also seen in 
patients with Jobs syndrome.23 In our study, IA was 
seen in 2 SCID patients who had no neutropenia. 
However, all 2ry immunodeficiency patients with 
IA were neutropenic cancer patients. In the 
meantime, one third only of the neutropenic cancer 
children with PCR-proven fungal infection had IA; 
the rest had IC. Therefore, Candida is the most 
commonly isolated fungus in this group of patients. 
Candida as a cause of fungal infection in 
immunocompromised patients in this study was 
more common than Aspergillus: 65% of patients 
were considered to have candidemia and 35% had 
IA. Badiee et al.15 also found Candida in 72.2% and 
Aspergillus in 27.3% of their samples. Early 
diagnosis of disseminated candidiasis is a challenge 
since in one study only 35-50% of patients with 
antibiotic resistant neutropenic fever had positive 
blood cultures for Candida and radiologic tests had 
low specificity in that patient population.24 In our 
study as well, 9 instances (30%) of PCR-proven 
candidemia were missed by blood culture which 
was also in agreement with the findings of Badiee 
et al.15  
As a diagnostic tool in IA, culture is not 
reliable as it is a relatively slow, insensitive and 
requires a specialized expertise for species 
determination.25 In the current study we found that 
patients who proved to have IA by PCR for 
Aspergillus had negative cultures for Aspergillus. 
This was in agreement with Gurtner et al.16 who 
found that blood samples showed no growth of 
Aspergillus although Aspergillosis was confirmed 
by PCR and histology.  
Out of the 17 patients diagnosed to have IFI by 
PCR, 14 were receiving antifungal treatment. In 
addition, the results of PCR did not differ 
significantly with the current intake of antifungal 
treatment. Mennink-Kersten et al.26 analyzed the 
kinetics of the markers used in vitro for the 
diagnosis of IA. The authors showed that GM and 
other fungal antigens were released when 
Aspergillus was found in exponential growth phase, 
while fungal DNA was released when the hyphae 
break up, a phenomenon which occurs naturally by 
autolysis when the amount of nutrients is limited or 
when antifungal agents are present.  In the study by 
Estrella and coworkers18 the two patients in whom 
the infection was detected by PCR at the same time 
as radiology or GM testing were the only two 
patients who were not on itraconazole prophylaxis. 
This strengthens the hypothesis that increased 
autolysis after the introduction of the antifungal 
agent leads to increased DNA release. 
Badiee et al.15 reported that in patients treated 
with antifungal therapy, the fungal PCR assay 
became negative after 14 days if treatment was 
successful, and PCR-ELISA was positive until 
death if treatment fails. In our study PCR was 
positive in a patient treated with Amphotericin B 
for 14 days who was still feverish till the day of 
sampling. However, other studies reported low 
sensitivity of PCR for Aspergillus, in patients on 
antifungal treatment (amphotericin B for 14 
days).27,28  
Combined bacteremia and fungemia was 
detected in this study in 2 patients: the first patient 
diagnosed as SCID, had concurrent infection with 
Staphylococcus aureus and Aspergillus and the 
second patient with congenital neutropenia had both 
Acinetobacter baumannii and Candida infection. 
Concurrent bacteremia and fungemia had been 
previously reported in patients with candidemia.29,30 
The fungemia in these 2 patients was diagnosed 
only by PCR and was missed by blood culture. 
Perhaps the usual microbiological techniques may 
be inadequate to detect fungemia when concomitant 
bacteremia is present. 31 
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In the current study, cases with IFI showed 
significantly increased CRP levels as compared to 
those without IFI. It has been reported that fever 
persisting at day 4 of admission, together with 
absolute monocytic count <100/mm3 and a CRP 
greater than 90 significantly increased the risk for 
IFI in children with cancer.32 Indeed there was no 
significant difference in the absolute neutrophil 
count between patients with and without fungal 
infection although it has been previously found that, 
in AML patients, the intensity of neutropenia can be 
a good predictor for IFI. 33   
In conclusion, real-time PCR proved superior 
to culture in the early diagnosis of IFI in patients 
with immunodeficiency before the appearance of 
the characteristic clinical and imaging signs. 
Reliance on blood culture alone at that stage would 
result in missing most of the positive cases with 
consequent delay in the initiation of specific 
treatment. Whether or not a negative PCR at that 
early stage of IFI could obviate the need for empiric 
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